1. Home
  2. PRSO vs MDXH Comparison

PRSO vs MDXH Comparison

Compare PRSO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.30

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.15

Market Cap

15.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
MDXH
Founded
2008
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
15.0M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
PRSO
MDXH
Price
$0.30
$0.15
Analyst Decision
Hold
Analyst Count
0
6
Target Price
N/A
★ $0.83
AVG Volume (30 Days)
★ 11.7M
1.3M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 81.23
N/A
EPS
N/A
★ N/A
Revenue
★ $14,573,000.00
N/A
Revenue This Year
N/A
$1.69
Revenue Next Year
$191.73
$11.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 5.99
N/A
52 Week Low
$0.28
$0.11
52 Week High
$2.10
$4.34

Technical Indicators

Market Signals
Indicator
PRSO
MDXH
Relative Strength Index (RSI) 36.98 28.57
Support Level N/A N/A
Resistance Level $0.46 $0.64
Average True Range (ATR) 0.04 0.02
MACD -0.01 0.01
Stochastic Oscillator 10.38 44.50

Price Performance

Historical Comparison
PRSO
MDXH

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: